The markets opened lower with the Dow losing 31 points to 20,919 despite an upbeat jobs report. Nasdaq slipped 2 points to 6,073.
On the upside
Immunomedics (Nasdaq: IMMU) terminated an exclusive global licensing agreement with Seattle Genetics and retained all rights to the metastatic triple negative breast cancer treatment IMMU-132.
Universal Display (Nasdaq: OLED) impressed with sharply higher first quarter earnings and revenue that surpassed expectations prompting the company to lift its full year forecast.
California Resources (NYSE: CRC) swung to a better than expected profit for the first quarter.
On the downside
Brightcove (Nasdaq: BCOV) widened losses more than expected for the first quarter.
Regulus Therapeutics (Nasdaq: RGLS) reported a wider than expected loss for the first quarter and announced the elimination of approximately 30% of its workforce.
Senior Vice President of Regulatory Affairs at Puma Biotechnology (NYSE: PBYI), Dr. Robert Charnas, resigned just before the Food and Drug Administration reviews the company's breast cancer treatment neratinib.
The broader S&P 500 index edged up a point to 2,390. Bitcoin soared $51 to $1525.
